PRIMARY RESEARCH

Open Access



LncRNA KCNQ1OT1 promotes cell proliferation, migration and invasion via regulating miR-129-5p/JAG1 axis in non-small cell lung cancer

Yan Wang¹, Lei Zhang², Jiasheng Yang¹ and Ruilin Sun^{1*}

Abstract

Background: Non-small cell lung cancer (NSCLC) is the most deadly cancer worldwide. LncRNA KCNQ1OT1 has been reported to be involved in the progression of various tumors, including NSCLC. However, the precise mechanism of KCNQ1OT1 in NSCLC requires further investigation.

Methods: The expression levels of KCNQ1OT1, miR-129-5p and JAG1 were detected by qRT-PCR or western blot. Kaplan–Meier survival analysis was used to assess the correlation between KCNQ1OT1 expression and the overall survival of NSCLC patients. CCK-8 assay was used to measure cell viability. Cell migration and invasion were detected by transwell assay. The targets of KCNQ1OT1 and miR-129-5p were predicted by bioinformatics, which was confirmed by dual-luciferase reporter assay or pull-down assay.

Results: KCNQ1OT1 expression was significantly enhanced, while miR-129-5p expression was dramatically reduced in NSCLC tissues and cells. Higher KCNQ1OT1 shortened overall survival and was positively associated with tumor stage and lymph node metastasis. KCNQ1OT1 knockdown inhibited proliferation, migration and invasion of NSCLC cells. Inhibition of miR-129-5p attenuated the inhibition of NSCLC cell viability, migration and invasion induced by KCNQ1OT1 knockdown. In addition, JAG1 was confirmed as a target of miR-129-5p. Knockdown of JAG1 reversed the effects of miR-129-5p knockdown on NSCLC progression. KCNQ1OT1 regulated JAG1 expression by sponging miR-129-5p in NSCLC cells.

Conclusion: KCNQ1OT1 induced proliferation, migration and invasion of NSCLC cells by sponging miR-129-5p and regulating JAG1 expression, indicating that KCNQ1OT1 was a therapeutic target for NSCLC.

Keywords: KCNQ1OT1, miR-129-5p, JAG1, Non-small cell lung cancer

Background

Lung cancer is the most deadly cancer in the world with high morbidity and mortality [1]. Lung cancer is divided into two subtypes of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Non-small cell lung cancer (NSCLC) is the most common subtype, accounting for more than 80% of all lung cancer [2]. Moreover, the prognosis of NSCLC patients is still poor, with a 5-year survival rate lower than 18% [3]. Although the research of NSCLC has been made progress in the past, the molecular mechanism of NSCLC still needs to be explored.

Full list of author information is available at the end of the article



© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

^{*}Correspondence: ewbcgp@163.com

¹ Department of Pulmonary and Critical Care Medicine, The Guangdong Second Provincial General Hospital, No. 466 Xingang Middle Rd, Haizhu District, 510000 Guangzhou, China

Wang et al. Cancer Cell Int (2020) 20:144 Page 2 of 11

Long noncoding RNAs (lncRNAs) are non-protein coding transcripts longer than 200 nucleotides in length [4]. Increasing evidence has shown that lncRNAs exerted significant regulatory effects on various biological processes and gene expression through multiple mechanisms [5]. KCNQ1 overlapping transcript 1 (KCNQ1OT1) was involved in the regulation of numerous genes within the kcnq1 domain [6]. LncRNA KCNQ1OT1 has been reported to play roles in the pathogenesis of various cancer, such as colorectal cancer [7], breast cancer [8] and tongue cancer [9]. In previous studies, KCNQ1OT1 facilitated progression of cholangiocarcinoma (CCA) by sponging miR-140-5p and regulating SOX4 expression [10]. However, the mechanism of KCNQ1OT1 in NSCLC still needs further research.

MicroRNAs (miRNAs) are non-protein-encoded short noncoding RNAs composed of 18-25 nucleotides. The roles of miRNAs in epigenetic regulation had progressed, in which miRNAs regulated the protein levels of target mRNAs [11]. A previous study revealed that miR-129-5p was down-regulated, and inhibited cell proliferation and EMT by negatively regulating HMGB1 in gastric cancer [12]. Moreover, the role of miR-129-5p in NSCLC have also been studied. LncRNA NNT-AS1 was a carcinogen in non-small cell lung cancer (NSCLC), and acted as a competing endogenous RNA (ceRNA) by targeting miR-129-5p in lung cancer [13]. However, the relationship between KCNQ1OT1 and miR-129-5p in the progression of NSCLC has not been elucidated.

Jagged1 (JAG1) has been reported to play a role in multiple types of cancer [14]. Previous studies have shown that JAG1 regulated tumor progression, including NSCLC. Tang et al. found that miR-377-3p suppressed cell proliferation and invasion via targeting JAG1 in ovarian cancer [15]. Wang et al. indicated that miR-26b was a tumor inhibitor through binding to JAG1 in cervical cancer [16].

In this study, we measured the expression levels of KCNQ1OT1, miR-129-5p and JAG1 in NSCLC tissues and cells. In addition, we explored the potential interactions between KCNQ1OT1 and miR-129-5p or miR-129-5p and JAG1. In conclusion, this study may provide novel therapeutic targets for NSCLC treatment.

Materials and methods

Tissue samples

All NSCLC tissues and the corresponding adjacent normal tissues were obtained from patients who underwent surgical resection at the Guangdong Second Provincial General Hospital. All patients did not undergo treatments prior to surgery. All patients were categorized according to the Eighth Edition of the American Joint Committee on Cancer TNM Staging System for lung

cancer. This research was approved by the Ethics Committee of the Guangdong Second Provincial General Hospital, and written informed consent was collected from all participants. All tissue samples were immediately frozen in liquid nitrogen and then stored at $-80\,^{\circ}\mathrm{C}$ until RNA extraction. The clinical characteristics of patients are summarized in Table 1.

Cell culture

Human lung epithelial cell line (BEAS-2B) and the NSCLC cell lines (A549, H1299, H460, H446 and H1975) were purchased from ATCC (American Type Culture Collection, Manassas, VA, USA) and were grown in Dulbecco's Modified Eagle Medium (DMEM; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Carlsbad, CA, USA) at 37 °C containing 5% CO₂.

Cell transfection

Small interfering RNA (siRNA) against KCNQ1OT1 (si-KCNQ1OT1, 5'-GGUAGAAUAGUUCUGUCUU-3'; si-KCNQ1OT1#2, 5'-GCCAAUAGCAACUGACUA A-3'; si-KCNQ1OT1#3, 5'-GCCACAUCUAACACC UAUA-3') and the negative control siRNA (si-NC), KCN-Q1OT1 overexpression plasmid (pcDNA-KCNQ1OT1) and the control (pcDNA-NC) were purchased from

Table 1 Correlation between KCNQ1OT1 expression and clinical characters in 60 patients with NSCLC

Characteristic	Case number	KCNQ1OT1 High	expression Low	P value
≥60	38	18	20	
< 60	22	12	10	
Gender				0.6042
Man	33	18	15	
Woman	27	12	15	
Smoking				0.4118
Yes	40	22	18	
No	20	8	12	
Histology				0.2949
Adenocarcinoma	35	20	15	
Squamous carci- noma	25	10	15	
Stage				0.0379
1+11	31	11	20	
III + IV	29	19	10	
Lymph node metastasis				0.0127
Positive	40	25	15	
Negative	20	5	15	

Wang et al. Cancer Cell Int (2020) 20:144 Page 3 of 11

RiboBio (Guangzhou, China). The miR-129-5p mimic and the mimic negative control (NC mimic), miR-129-5p inhibitor and the negative control (NC inhibitor), siRNA against JAG1 (si-JAG1, 5'-GGCCAAGCCUUGUGU AAAU-3') and the corresponding negative control (si-NC) were synthesized by Genelily BioTech (Shanghai, China). Cells were transfected by Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer's requirements.

Quantitative real-time PCR

Total RNA was isolated from tissues and cells using TRIzol reagent (Invitrogen) by the protocols of the manufacturer. The first strand cDNA was synthesized using the High-Capacity cDNA Reverse Transcription Kits (Thermo Fisher Scientific). The expression levels were detected using SYBR Green Mixture (Takara, Dalian, China). GAPDH or U6 was used as the endogenous control. Primers as follows: KCNQ1OT1 (forward, 5'-AGG GTGACAGTGTTTCATAGGCT-3'; reverse, 5'-GAG GCACATTCATTCGTTGGT-3'), miR-129-5p (forward, 5'-ACCCAGTGCGATTTGTCA-3'; reverse, GTACTGGAAGATGGACC-3'), JAG1 (forward, 5'-GTC CATGCAGAACGTGAACG-3'; reverse, 5'-GCGGGA CTGATACTCCTTGA-3'), GAPDH (forward, 5'-TCG CCAGCCGAGCCACATC-3'; reverse, 5'-CGTTCTCAG CCTTGACGGTGC-3'), U6 (forward, 5'-CGATACAGA GAAGATTAGCATGGC-3'; reverse, 5'-AACGCTTCA CGAATTTGCGT-3').

CCK-8 assay

The viability of cells was detected with Cell Counting Kit-8 (CCK-8; Dojindo, Kumamoto, Japan). First, 100 μ l of cell suspension (1.0 \times 10⁵ cells per well) were seeded into 96-well plates and cultured at 37 °C. Then, 10 μ l CCK-8 solution was added to each well after incubation for 48 h. After 4 h, the absorbance was read at 450 nm using Microplate Reader (Bio-Rad, Hercules, CA, USA).

Transwell assay

Cell migration and invasion ability were detected using transwell assay. For cell migration, the transfected cells were plated (1.0×10^5 cells per well) in the upper chamber of a 24-well transwell containing 8 µm polycarbonate membrane (Millipore, Billerica, MA, USA). The serumfree DMEM was added into the upper chamber, and DMEM containing 10% FBS as a chemoattractant was added to the lower chamber. Then, cells were cultured for 48 h at 37 °C, and the cells migrated to the lower surface were fixed with methanol and stained with 0.1% crystal violet. At last, the cells were counted with microscopy. For cell invasion, transwell chambers were coated with

Matrigel (Millipore), and other experimental procedures were performed as previously described.

Dual-luciferase reporter assay

The putative binding sites of KCNQ1OT1 and miR-129-5p or miR-129-5p and JAG1 were predicted by LncBase Predicted v.2 or StarBase v2.0. The fragments of KCNQ1OT1 containing wild-type (wt) or mutant (mut) binding sites of miR-129-5p were inserted into pGL3 luciferase reporter plasmids (Promega, Madison, WI, USA), and were co-transfected with miR-129-5p mimic or NC mimic into A549 and H460 cells using Lipofectamine 2000 (Invitrogen). In addition, the sequences of JAG1 3'UTR containing wild-type (wt) or mutant (mut) binding sites of miR-129-5p was cloned into pGL3 vectors (Promega). A549 and H460 cells were co-transfected with miR-129-5p mimic or NC mimic and corresponding luciferase reporter vector using Lipofectamine 2000 (Invitrogen). After the transfection for 48 h, Dual-Luciferase Reporter Assay System (Promega) was used for luciferase activity analysis according to the manufacturer's instructions.

RNA pull-down assay

RNA pull-down assay was performed as previously described [17]. Biotin-labeled wild-type KCNQ1OT1 (Bio-KCNQ1OT1), mutant KCNQ1OT1 (Bio-KCNQ1OT1-MUT) and the control (Bio-NC) were purchased from RiboBio. Briefly, the biotinylated RNA was incubated with total RNA extracted from A549 and H460 cell lysates overnight at 4 °C. Then, the biotin-coupled RNA complexes were pulled down using M-280 Streptavidin Dynabeads (Invitrogen) at room temperature for 2 h. After RNA isolation, the abundance of miR-129-5p was detected by qRT-PCR.

Western blot assay

After transfection, A549 and H460 cells were harvested and lysed in RIPA lysis buffer (Thermo Fisher Scientific). Total protein was quantified using the BCA Protein Assay Kit (Pierce, Appleton, WI, USA) with the protocols of the manufacturer. Then, the proteins were separated by SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore). Furthermore, the membranes were blocked by 5% non-fat milk (Nestlé, Shuangcheng, China) for 2 h at 37 °C, and then incubated with primary antibodies against JAG1 (1:2000; Abcam, Cambridge, UK) or GAPDH (1:2000; Abcam) overnight at 4 °C. Subsequently, the membranes were washed three times with TBST and interacted with horseradish peroxidase (HRP)-conjugated secondary antibody (1:4000; Abcam) for 2 h at room temperature. Finally, the protein bands were visualized via enhanced

Wang et al. Cancer Cell Int (2020) 20:144 Page 4 of 11

chemiluminescence system (Thermo Fisher Scientific) and quantitated by ImageJ software (National Institutes of Health, Bethesda, MD, USA). GAPDH was regarded as an endogenous reference.

Statistical analysis

All data were displayed as the mean ± standard deviation (SD) from three independent experiments. Differences between the two groups were analyzed by Student's *t* test, and multiple groups were analyzed by one-way analysis of variance (one-way ANOVA). Statistical analysis was performed using Graphpad Prism 7.0 software (GraphPad, San Diego, CA, USA). At *P*-value < 0.05, the difference was considered to be statistically significant.

Results

KCNQ1OT1 was upregulated in NSCLC tissues and cells and correlated with poor prognosis

In order to verify the differential expression of KCN-Q1OT1 in NSCLC tissues and cells, qRT-PCR was performed to detect expression levels. The results revealed that KCNQ1OT1 expression was significantly upregulated in NSCLC tissues compared to adjacent

non-tumor tissues (Fig. 1a). Similarly, the expression of KCNQ1OT1 was dramatically higher in NSCLC cells (A549, H1299, H460, H446 and H1975) than that in BEAS-2B cells (Fig. 1b). Furthermore, Kaplan-Meier survival analysis showed that higher KCNQ1OT1 expression resulted in poor overall survival compared with lower KCNQ1OT1 expression (Fig. 1c). Finally, we also investigated the correlation between KCNQ1OT1 expression levels and clinical pathological features. The data indicated that KCNQ1OT1 expression was not associated with patient age, gender, smoking and histology, but was correlated with tumor stage and lymph node metastasis (Table 1). All these data suggested that KCNQ1OT1 expression was related to NSCLC prognosis and might play crucial roles in NSCLC development and progression.

KCNQ1OT1 knockdown inhibited proliferation, migration and invasion of NSCLC cells

To investigate the effects of KCNQ1OT1 on NSCLC progression, A549 and H460 cells were transfected with si-KCNQ1OT1, si-KCNQ1OT1#2, si-KCNQ1OT1#3 or si-NC. First, qRT-PCR results showed




Fig. 1 KCNQ1OT1 was upregulated in NSCLC tissues and cells and correlated with poor prognosis. **a** qRT-PCR was used to detect KCNQ1OT1 expression in NSCLC tissues and adjacent normal tissues. **b** The KCNQ1OT1 expression was detected in normal lung epithelial cell line (BEAS-2B) and the NSCLC cell lines (A549, H1299, H460, H446 and H1975) by qRT-PCR. **c** Kaplan–Meier survival analysis was performed to investigate the correlation between KCNQ1OT1 expression and overall survival rate of NSCLC patients. *P < 0.05

Wang et al. Cancer Cell Int (2020) 20:144 Page 5 of 11

that the si-KCNQ1OT1 group had the most significant down-regulation after transfection with si-KCNQ1OT1, si-KCNQ1OT1#2 or si-KCNQ1OT1#3, so si-KCNQ1OT1 was selected for subsequent research (Fig. 2a and Additional file 1: Figure S1). CCK-8 assay and transwell assay exhibited that KCNQ1OT1 knockdown dramatically suppressed cell viability (Fig. 2b), migration (Fig. 2c) and invasion (Fig. 2d) in A549 and H460 cells. These data demonstrated that KCNQ1OT1 knockdown blocked cell proliferation, migration and invasion of NSCLC cells.

KCNQ10T1 directly targeted miR-129-5p in NSCLC cells

To verify whether KCNQ1OT1 could act as a ceRNA by competitively binding miRNAs in NSCLC, we predicted that KCNQ1OT1 had putative binding sites with miR-129-5p by LncBase Predicted v.2 (Fig. 3a). For further validation, dual-luciferase reporter assay was performed. The results showed that cells co-transfected with wt-KCNQ1OT1 and miR-129-5p mimic had strikingly lower luciferase activity than other co-transfected complexes (Fig. 3b, c). Moreover, RNA pull-down assay further confirmed that KCNQ1OT1 bound to




Fig. 2 KCNQ10T1 knockdown inhibited proliferation, migration and invasion of NSCLC cells. A549 and H460 cells were transfected with si-KCNQ10T1 or the control si-NC. **a** The expression of KCNQ10T1 was detected by qRT-PCR in transfected cells. **b** Cell proliferation was evaluated using CCT-8 assay. **c**, **d** The migrated and invaded cells were measured by transwell assay. **P* < 0.05

Wang et al. Cancer Cell Int (2020) 20:144 Page 6 of 11




Fig. 3 KCNQ1OT1 directly targeted miR-129-5p in NSCLC cells. a The putative binding sites of KCNQ1OT1 and miR-129-5p were shown. b, c Luciferase activity was examined in A549 and H460 cells co-transfected with wt-KCNQ1OT1 or mut-KCNQ1OT1 and miR-129-5p mimic or NC mimic. d RNA pull-down assay was performed to confirm the relationship between KCNQ1OT1 and miR-129-5p. e Transfection efficiency was measured using qRT-PCR in A549 and H460 cells introduced with pcDNA-NC or pcDNA-KCNQ1OT1. f, g A549 and H460 cells were transfected with pcDNA-NC, pcDNA-KCNQ1OT1, si-NC or si-KCNQ1OT1, and miR-129-5p expression was detected by qRT-PCR after transfection. h MiR-129-5p expression in normal tissues and NSCLC tissues was examined by qRT-PCR. i The correlation between KCNQ1OT1 and miR-129-5p was exhibited. j MiR-129-5p expression in BEAS-2B cells and NSCLC cell lines (A549 and H460) was detected by qRT-PCR. k MiR-129-5p level was examined by qRT-PCR in A549 and H460 cells transfected with NC mimic, miR-129-5 mimic, NC inhibitor or miR-129-5 inhibitor. *P<0.05

miR-129-5p (Fig. 3d). Besides, the overexpression efficiency of KCNQ1OT1 was determined by qRT-RCR (Fig. 3e and Additional file 2: Figure S2). Furthermore, KCNQ1OT1 overexpression significantly reduced miR-129-5p expression, and KCNQ1OT1 knockdown strikingly increased miR-129-5p expression in A549 and H460 cells (Fig. 3f, g). In addition, miR-129-5p expression was remarkably down-regulated in NSCLC tissues and cells (Fig. 3h, j), and was negatively correlated with KCNQ1OT1 expression in NSCLC tissues (Fig. 3i). Also, the overexpression efficiency and suppression efficiency of miR-129-5p were determined by qRT-PCR (Fig. 3k). These results revealed that KCNQ1OT1 directly bound to miR-129-5p in NSCLC.

Inhibition of miR-129-5p reversed the effects of KCNQ1OT1 knockdown on proliferation, migration, invasion of NSCLC cells

To further investigate the effects of miR-129-5p on NSCLC development, A549 and H460 cells were transfected with si-NC+NC inhibitor, si-KCNQ1OT1+NC inhibitor or si-KCNQ1OT1+miR-129-5p inhibitor. The results showed that transfection with miR-129-5p inhibitor attenuated the increase in miR-129-5p expression caused by KCNQ1OT1 silencing (Fig. 4a). Moreover, simultaneous knockdown of KCNQ1OT1 and miR-129-5p reversed the inhibitory effects of KCNQ1OT1 depletion on cell proliferation (Fig. 4b), migration (Fig. 4c) and invasion (Fig. 4d) of A549 and H460

Wang et al. Cancer Cell Int (2020) 20:144 Page 7 of 11




Fig. 4 Inhibition of miR-129-5p reversed the effects of KCNQ1OT1 knockdown on NSCLC progression. (A-D) A549 and H460 cells were transfected with si-NC + NC inhibitor, si-KCNQ1OT1 + NC inhibitor or si-KCNQ1OT1 + miR-129-5p inhibitor. **a** The expression of miR-129-5p was detected by qRT-PCR. **b** Cell proliferation was detected by CCK-8 assay. **c** The migrated cells were measured by transwell assay. **d** The invaded capacity was evaluated by transwell assay. *P < 0.05

cells. These results indicated that inhibition of miR-129-5p could abrogate the inhibitory effects of KCN-Q1OT1 knockdown on NSCLC progression.

MiR-129-5p targeted JAG1 in NSCLC cells

StarBase v2.0 predicted that miR-129-5p might bind to JAG1 (Fig. 5a). Then, dual-luciferase reporter assay was performed to verify whether JAG1 was a target for miR-129-5p. The results suggested that miR-129-5p mimic significantly decreased the luciferase activity in A549 and H460 cells transfected with wt-JAG1, whereas luciferase activity could not be regulated when the binding sites were mutated (Fig. 5b, c). To further explore whether JAG1 was regulated by miR-129-5p, western blot results revealed that miR-129-5p inhibition obviously increased the protein level of JAG1, while miR-129-5p mimic markedly reduced the protein level of JAG1 in A549 and H460 cells compared to the negative control (Fig. 5d, e). These data suggested that JAG1 was a target gene of miR-129-5p.

MiR-129-5p modulated NSCLC progression by targeting JAG1

To further determine the effects of miR-129-5p on NSCLC progression, A549 and H460 cells were

transfected with NC inhibitor, miR-129-5p inhibitor, miR-129-5p inhibitor+si-NC or miR-129-5p inhibitor+si-JAG1. Firstly, western blot analysis revealed that transfection with si-JAG1 alleviated the elevation in JAG1 protein expression caused by miR-129-5p knockdown (Fig. 6a). Moreover, CCK-8 assay showed that down-regulation of miR-129-5p obviously increased cell viability, while the effect was eliminated by silencing of JAG1 (Fig. 6b). Transwell assay revealed that knockdown of miR-129-5p remarkably promoted cell migration and invasion, whereas the impact was reversed after transfection with si-JAG1 (Fig. 6c, d). These results indicated that miR-129-5p might suppress cell proliferation, migration and invasion in NSCLC by modulating JAG1.

KCNQ1OT1 regulated JAG1 by sponging miR-129-5p in NSCLC cells

The western blot results revealed that KCNQ1OT1 knockdown significantly reduced the protein levels of JAG1, whereas the miR-129-5p inhibitor restored the JAG1 expression in A549 and H460 cells (Fig. 7a, b). Moreover, JAG1 expression was overtly increased in NSCLC tissues and was positively correlated with KCNQ1OT1 expression (Additional file 3: Figure S3A and AB). These results suggested that KCNQ1OT1

Wang et al. Cancer Cell Int (2020) 20:144 Page 8 of 11




Fig. 5 MiR-129-5p targeted JAG1 in NSCLC cells. **a** The putative binding sites of miR-129-5p and JAG1. **b**, **c** Luciferase activity was examined in A549 and H460 cells co-transfected with wt-JAG1 or mut-JAG1 and miR-129-5p mimic or NC mimic. **d** The protein level of JAG1 in A549 and H460 cells transfected with NC inhibitor or miR-129-5p inhibitor. **e** The protein level of JAG1 in A549 and H460 cells transfected with NC mimic or miR-129-5p mimic. *P < 0.05

modulated JAG1 expression by regulating miR-129-5p in NSCLC cells.

Discussion

With the great achievements in diagnosis and treatment, the survival time of NSCLC has increased, but the prognosis of NSCLC is still poor [18]. In recent years, the studies suggested that lncRNAs dysregulation was associated with the progression of cancers, including NSCLC [19]. To elucidate the molecular mechanism of lncRNAs in the prognosis of NSCLC is meaningful.

Recent studies exhibited that lncRNA KCNQ1OT1 was upregulated in various cancers. A previous study suggested that KCNQ1OT1 facilitated tumor growth by competitively sponging miR-504 and up-regulating cyclin-dependent kinase 16 (CDK16) in hepatocellular carcinoma [20]. A previous research revealed that KCNQ1OT1 was upregulated in early stage lung cancer and was associated with prognosis in LC patients by suppressing cell proliferation [21]. Furthermore, Dong et al. demonstrated that KCNQ1OT1 was markedly upregulated in NSCLC tissues and cells, and promoted NSCLC cells proliferation, migration, and invasion by

Wang et al. Cancer Cell Int (2020) 20:144 Page 9 of 11




Fig. 6 MiR-129-5p modulated NSCLC progression by targeting JAG1. (A-D) A549 and H460 cells were transfected with NC inhibitor, miR-129-5p inhibitor, miR-129-5p inhibitor + si-JAG1. **a** The protein level of JAG1 was detected by western blot. **b** Cell proliferation was detected by CCK-8 assay. **c** The migrated cells were measured by transwell assay. **d** Cell invasion was evaluated by transwell assay after transfection. **P* < 0.05

regulating the KCNQ1OT1/miR-27b-3p/HSP90AA1 axis [22]. Consistent with previous study, the level of KCNQ1OT1 in NSCLC tissues and cell lines was dramatically higher than that in non-tumor tissues and cells. These results revealed that KCNQ1OT1 might exhibit vital roles in NSCLC development and progression.

It has been reported that lncRNAs could be used as competitive endogenous RNAs (ceRNAs) [23]. This study showed that KCNQ1OT1 could competitively bind to miR-129-5p. MiR-129-5p has been reported as an anti-tumor role in many cancers. In ovarian cancer, miR-129-5p was significantly downregulated in OC tissues and cells, and miR-129-5p acting as tumor suppressor inhibited cell proliferation and promoted apoptosis of OC cell by attenuating the effects of PCAT-1 [24]. In osteosarcomas, MALAT1 increased stem cell-like properties by regulating the expression of RET via sponging miR-129-5p [25]. Moreover, the effects of miR-129-5p in NSCLC have also been reported. MiR-129-5p suppressed NSCLC stemness and chemoresistance by targeting DLK1 [26]. In our study, we demonstrated that miR-129-5p was dramatically down-regulated in NSCLC tissues and cells. Meanwhile, miR-129-5p had binding sites with KCNQ1OT1. Inhibition of miR-129-5p could abolish the effects of KCNQ1OT1 knockdown on the progression of NSCLC.

JAG1 is a Notch ligand that plays a vital role in a variety of signaling pathways [27]. Recent evidence suggests that JAG1 was an oncogene in NSCLC by inducing cell metastasis [28]. In this study, we found that JAG1 was inhibited by miR-129-5p in NSCLC, and JAG1 knockdown reversed the effects of miR-129-5p inhibition. In short, KCNQ1OT1 regulated JAG1 expression by sponging miR-129-5p in NSCLC cells.

Conclusion

In conclusion, this study suggested that KCNQ1OT1 and JAG1 were upregulated, while miR-129-5p was down-regulated in NSCLC tissues and cells. Knockdown of KCNQ1OT1 significantly inhibited proliferation, migration and invasion of NSCLC cells. Meanwhile, miR-129-5p inhibition reversed the effects of KCNQ1OT1 knockdown on the progression of NSCLC. In a word, we found that KCNQ1OT1 promoted the NSCLC progression by regulating the KCNQ1OT1/miR-129-5p/JAG1 axis, which provides therapeutic targets for NSCLC.

Wang et al. Cancer Cell Int (2020) 20:144 Page 10 of 11




Fig. 7 KCNQ1OT1 regulated JAG1 by sponging miR-129-5p in NSCLC cells. a, b A549 and H460 cells were transfected with si-NC, si-KCNQ1OT1, si-KCNQ1OT1 + NC inhibitor, or si-KCNQ1OT1 + miR-129-5p inhibitor. The protein level of JAG1 was detected by western blot. *P < 0.05

Supplementary information

Supplementary information accompanies this paper at https://doi. org/10.1186/s12935-020-01225-8.

Additional file 1: Figure S1. The knockdown efficiency of KCNQ1OT1 was determined by gRT-PCR in A549 and H460 cells transfected with si-KCNQ1OT1, si-KCNQ1OT1#2 or si-KCNQ1OT1#3. *P < 0.05.

Additional file 2: Figure S2. The expression of KCNQ1OT1 was detected in BEAS-2B cells, NSCLC cells and NSCLC cells transfected with pcDNA-NC or pcDNA-KCNQ1OT1. *P < 0.05.

Additional file 3: Figure S3. (A) The expression of JAG1 mRNA in normal tissues and NSCLC tissues was detected by qRT-PCR. (B) The correlation between JAG1 mRNA and KCNQ1OT1 in NSCLC tissues was analyzed by Spearman's correlation analysis. *P < 0.05.

Abbreviations

NSCLC: Non-small cell lung cancer; SCLC: Small cell lung cancer; CCA: Cholangiocarcinoma; miRNAs: MicroRNAs.

Acknowledgements

None.

Authors' contributions

YW conceived and designed the experiments; LZ performed the experiments, Funding acquisition; JY contributed reagents/materials/analysis tools; RS wrote the paper. All authors read and approved the final manuscript.

Funding

This study was supported by the Guangdong Science and Technology Project: Effect of inflammatory factor HMGB1 on lung cancer microenvironment (Grants No. 2016A020215191).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Ethics approval and consent to participate

This research was approved by the Ethics Committee of the Guangdong Second Provincial General Hospital, and written informed consent was collected from all participants.

Consent for publication

Informed consent was obtained from all patients.

Competing interests

The authors declare that they have no competing interests.

Author details

¹ Department of Pulmonary and Critical Care Medicine, The Guangdong Second Provincial General Hospital, No. 466 Xingang Middle Rd, Haizhu District, 510000 Guangzhou, China. ² Department of Transplant Centre, The Second Affiliated Hospital of Guangzhou Medical University, 510000 Guangzhou, China.

Received: 11 December 2019 Accepted: 20 April 2020 Published online: 01 May 2020

Wang et al. Cancer Cell Int (2020) 20:144 Page 11 of 11

References

- Kaderbhai C, Tharin Z, Ghiringhelli F. The role of molecular profiling to predict the response to immune checkpoint inhibitors in lung cancer. Cancers (Basel). 2019;11:2.
- Mukherjee A, Paul M, Mukherjee S. Recent progress in the theranostics application of nanomedicine in lung cancer. Cancers (Basel). 2019;11:5.
- Hirono T, Jingushi K, Nagata T, Sato M, Minami K, Aoki M, Takeda AH, Umehara T, Egawa H, Nakatsuji Y, et al. MicroRNA-130b functions as an oncomiRNA in non-small cell lung cancer by targeting tissue inhibitor of metalloproteinase-2. Sci Rep. 2019;9(1):6956.
- Shields EJ, Petracovici AF, Bonasio R. IncRedibly versatile: biochemical and biological functions of long noncoding RNAs. Biochem J. 2019;476(7):1083–104.
- Zhang L, Dong Y, Wang Y, Gao J, Lv J, Sun J, Li M, Wang M, Zhao Z, Wang J, et al. Long non-coding RNAs in ocular diseases: new and potential therapeutic targets. FEBS J. 2019;286(12):2261–72.
- Kanduri C. Kcnq1ot1: a chromatin regulatory RNA. Semin Cell Dev Biol. 2011;22(4):343–50.
- Bian Y, Gao G, Zhang Q, Qian H, Yu L, Yao N, Qian J, Liu B, Qian X. KCNQ10T1/miR-217/ZEB1 feedback loop facilitates cell migration and epithelial-mesenchymal transition in colorectal cancer. Cancer Biol Ther. 2019;20(6):886–96.
- Feng W, Wang C, Liang C, Yang H, Chen D, Yu X, Zhao W, Geng D, Li S, Chen Z, et al. The dysregulated expression of KCNQ10T1 and its interaction with downstream factors miR-145/CCNE2 in breast cancer cells. Cell Physiol Biochem. 2018;49(2):432–46.
- Zhang S, Ma H, Zhang D, Xie S, Wang W, Li Q, Lin Z, Wang Y. LncRNA KCNQ10T1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Ezrin/Fak/Src signaling. Cell Death Dis. 2018;9(7):742.
- Sun H, Li Y, Kong H, Dai S, Qian H. Dysregulation of KCNQ10T1 promotes cholangiocarcinoma progression via miR-140-5p/SOX4 axis. Arch Biochem Biophys. 2018;658:7–15.
- 11. Yao Q, Chen Y, Zhou X. The roles of microRNAs in epigenetic regulation. Curr Opin Chem Biol. 2019;51:11–7.
- 12. Wang S, Chen Y, Yu X, Lu Y, Wang H, Wu F, Teng L. miR-129-5p attenuates cell proliferation and epithelial mesenchymal transition via HMGB1 in gastric cancer. Pathol Res Pract. 2019;215(4):676–82.
- Shen Q, Jiang Y. LncRNA NNT-AS1 promotes the proliferation, and invasion of lung cancer cells via regulating miR-129-5p expression. Biomed Pharmacother. 2018;105:176–81.
- Grochowski CM, Loomes KM, Spinner NB. Jagged1 (JAG1): structure, expression, and disease associations. Gene. 2016;576(1 Pt 3):381–4.

- Tang L, Yang B, Cao X, Li Q, Jiang L, Wang D. MicroRNA-377-3p inhibits growth and invasion through sponging JAG1 in ovarian cancer. Genes Genomics. 2019;41(8):919–26.
- Wang L, Wang W, Wu Y. MicroRNA-26b acts as an antioncogene and prognostic factor in cervical cancer. Oncol Lett. 2019;17(3):3418–24.
- Panda AC, Martindale JL, Gorospe M. Affinity pulldown of biotinylated RNA for detection of protein-RNA complexes. Bio Protoc. 2016;6:24.
- Lu T, Wang Y, Chen D, Liu J, Jiao W. Potential clinical application of IncR-NAs in non-small cell lung cancer. Onco Targets Ther. 2018;11:8045–52.
- 19. Wei MM, Zhou GB. Long non-coding RNAs and Their Roles in Non-small-cell Lung Cancer. Genomics Proteom Bioinform. 2016;14(5):280–8.
- Li C, Miao R, Zhang J, Qu K, Liu C. Long non-coding RNA KCNQ10T1 mediates the growth of hepatocellular carcinoma by functioning as a competing endogenous RNA of miR-504. Int J Oncol. 2018;52(5):1603–12.
- Sun X, Xin Y, Wang M, Li S, Miao S, Xuan Y, Wang Y, Lu T, Liu J, Jiao W. Overexpression of long non-coding RNA KCNQ10T1 is related to good prognosis via inhibiting cell proliferation in non-small cell lung cancer. Thorac Cancer. 2018;9(5):523–31.
- Dong Z, Yang P, Qiu X, Liang S, Guan B, Yang H, Li F, Sun L, Liu H, Zou G, et al. KCNQ1OT1 facilitates progression of non-small-cell lung carcinoma via modulating miRNA-27b-3p/HSP90AA1 axis. J Cell Physiol. 2019:234(7):11304–14.
- 23. Yamamura S, Imai-Sumida M, Tanaka Y, Dahiya R. Interaction and cross-talk between non-coding RNAs. Cell Mol Life Sci. 2018;75(3):467–84.
- Gu LP, Jin S, Xu RC, Zhang J, Geng YC, Shao XY, Qin LB. Long non-coding RNA PCAT-1 promotes tumor progression by inhibiting miR-129-5p in human ovarian cancer. Arch Med Sci. 2019;15(2):513–21.
- Chen Y, Huang W, Sun W, Zheng B, Wang C, Luo Z, Wang J, Yan W. LncRNA MALAT1 promotes cancer metastasis in osteosarcoma via activation of the PI3K-Akt signaling pathway. Cell Physiol Biochem. 2018;51(3):1313–26.
- Ma Z, Cai H, Zhang Y, Chang L, Cui Y. MiR-129-5p inhibits non-small cell lung cancer cell stemness and chemoresistance through targeting DLK1. Biochem Biophys Res Commun. 2017;490(2):309–16.
- 27. Azimi M, Brown NL. Jagged1 protein processing in the developing mammalian lens. Biol Open. 2019;8:3.
- 28. Chang WH, Ho BC, Hsiao YJ, Chen JS, Yeh CH, Chen HY, Chang GC, Su KY, Yu SL. JAG1 is associated with poor survival through inducing metastasis in lung cancer. PLoS ONE. 2016;11(3):e0150355.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- $\bullet\,$ thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

